SPRO Stock: Price, Forecast, Financials & AI Analysis

Loading...

Loading chart...

High

2.280

Open

2.230

VWAP

2.21

Vol

629.52K

Mkt Cap

127.38M

Low

2.150

Amount

1.39M

EV/EBITDA(TTM)

5.03

Total Shares

57.90M

EV

71.25M

EV/OCF(TTM)

9.84

P/S(TTM)

2.14

Spero Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on identifying and developing novel treatments for rare diseases and diseases caused by multi-drug resistant (MDR) bacterial infections with unmet need. Its product candidate SPR720 is an investigational, chemically stable phosphate ester prodrug that is converted in vivo to SPR719 for the treatment of nontuberculous mycobacterial (NTM) pulmonary disease. Its clinical stage product candidate, tebipenem HBr is an investigational oral carbapenem antibiotic being developed for the treatment of complicated urinary tract infections (cUTIs) including acute pyelonephritis (AP) to help patients potentially reduce duration of in-patient therapy.

Show More

Events Timeline

(ET)

2026-06-17

11:30:00

GSK and Spero Therapeutics Get FDA Approval for Utebzi Antibiotic

2025-12-19 (ET)

2025-12-19

08:20:00

Spero Therapeutics Receives $25 Million Milestone Payment Triggered by GSK's NDA Submission

2025-11-28 (ET)

2025-11-28

08:08:43

Spero Therapeutics Reveals Inducement Grant in Accordance with Nasdaq Listing Regulations

2025-10-21 (ET)

2025-10-21

05:46:08

Spero Therapeutics and GSK Reveal Efficacy and Safety Outcomes of PIVOT-PO Trial

2025-05-28 (ET)

2025-05-28

07:17:32

GSK reports PIVOT-PO study for tebipenem HBr stopped early for efficacy

2025-05-28

07:05:59

Spero Therapeutics, GSK announce Phase 3 PIVOT-PO trial met primary endpoint

2025-04-28 (ET)

2025-04-28

16:08:20

Spero Therapeutics appoints Esther Rajavelu will serve as CEO

2025-03-27 (ET)

2025-03-27

16:15:34

Spero Therapeutics reports Q4 EPS (38c), consensus (31c)

News

Globenewswire

06-29Globenewswire

Kailera Appoints New Chief Corporate Affairs Officer

NASDAQ.COM

06-19NASDAQ.COM

Biotech Sector Sees FDA Approvals and Layoffs

NASDAQ.COM

06-18NASDAQ.COM

GSK and Spero Gain FDA Approval for New Antibiotic

Newsfilter

06-17Newsfilter

First Oral Carbapenem Antibiotic Approved in the US

Newsfilter

06-17Newsfilter

First Oral Carbapenem Antibiotic Approved in the US

seekingalpha

06-17seekingalpha

GSK and Spero's Utebzi Approved by FDA for UTIs

2 Analyst Rating

Wall Street analysts forecast SPRO stock price to rise

0 Buy

2 Hold

0 Sell

Hold

Current: 0.000

Low

4.00

Averages

4.00

High

4.00

Current: 0.000

Low

4.00

Averages

4.00

High

4.00

No data

No data

Valuation Metrics

The current forward P/E ratio for Spero Therapeutics Inc (SPRO.O) is 0.00, compared to its 5-year average forward P/E of -1.92. For a more detailed relative valuation and DCF analysis to assess Spero Therapeutics Inc's fair value, Click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

dotted line Image

N/A

5Y Average PE

-1.92

Current PE

0.00

Overvalued PE

0.18

Undervalued PE

-4.01

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

dotted line Image

N/A

5Y Average EV/EBITDA

-0.83

Current EV/EBITDA

0.00

Overvalued EV/EBITDA

0.95

Undervalued EV/EBITDA

-2.60

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

dotted line Image

N/A

5Y Average PS

10.63

Current PS

0.00

Overvalued PS

25.56

Undervalued PS

-4.29

Financials

AI Analysis

Annual

Quarterly

Related Community Screener

Penny stock pullback this week

Intellectia · 26 candidates

Market Cap: 50.00M - 2.00BRegion: USPrice: $0.50 - $5.00List Exchange: XNYS, XNAS, XASEMoving Average Relationship: PriceAboveMA200Week Price Change Pct: $-15.00 - $-3.00Month Price Change Pct: >= $10.00

Ticker

Name

Market Cap$

Estrella Immunopharma Inc

67.41M

Gold Resource Corp

273.54M

Eledon Pharmaceuticals Inc

262.83M

Ballard Power Systems Inc

987.00M

Nkarta Inc

208.17M

Trilogy Metals Inc

717.98M

top penny stocks to buy today

Intellectia · 146 candidates

Price: $0.10 - $5.00Rsi Category: moderateRelative Vol: >= 1.50List Exchange: XNYS, XNAS, XASEMoving Average Relationship: PriceAboveMA20One Day Predict Return: >= 0.0%Monthly Average Dollar Volume: >= 500,000

Ticker

Name

Market Cap$

Xiao-I Corp

26.23M

Virgin Galactic Holdings Inc

241.78M

ThredUp Inc

482.44M

OFS Credit Company Inc

85.23M

Spero Therapeutics Inc

157.46M

Brazil Potash Corp

181.76M

what penny stocks should we attack

Intellectia · 32 candidates

Market Cap: 50.00M - 1.50BRegion: USPrice: $0.50 - $5.00Quarter Revenue Yoy Growth: >= 10.0%Net Margin: >= 0.00List Exchange: XNYS, XNAS, XASEMonthly Average Dollar Volume: >= 500,000

Ticker

Name

Market Cap$

Uranium Royalty Corp

518.53M

Orchestra Biomed Holdings Inc

249.30M

Compugen Ltd

219.37M

Horizon Technology Finance Corp

212.25M

Ovid Therapeutics Inc

386.63M

Gold Resource Corp

194.23M

stocks under 200 ma for 52 weeks

Intellectia · 195 candidates

Market Cap: <= 200.00MYear Price Change Pct: >= $20.00

Ticker

Name

Market Cap$

Palatin Technologies Inc

29.61M

Sol Gel Technologies Ltd

187.20M

AIM ImmunoTech Inc

4.25M

JFB Construction Holdings

182.67M

Sound Group Inc

59.32M

Paramount Gold Nevada Corp

184.39M

Whales Holding SPRO

Trading Trends

People Also Watch

Frequently Asked Questions

What is Spero Therapeutics Inc (SPRO) stock price today?

The current price of SPRO is 2.2 USD — it has decreased -0.9

What is Spero Therapeutics Inc (SPRO)'s business?

Spero Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on identifying and developing novel treatments for rare diseases and diseases caused by multi-drug resistant (MDR) bacterial infections with unmet need. Its product candidate SPR720 is an investigational, chemically stable phosphate ester prodrug that is converted in vivo to SPR719 for the treatment of nontuberculous mycobacterial (NTM) pulmonary disease. Its clinical stage product candidate, tebipenem HBr is an investigational oral carbapenem antibiotic being developed for the treatment of complicated urinary tract infections (cUTIs) including acute pyelonephritis (AP) to help patients potentially reduce duration of in-patient therapy.

What is the price predicton of SPRO Stock?

Wall Street analysts forecast SPRO stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for SPRO is4.00 USD with a low forecast of 4.00 USD and a high forecast of 4.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

What is Spero Therapeutics Inc (SPRO)'s revenue for the last quarter?

Spero Therapeutics Inc revenue for the last quarter amounts to 258.00K USD, decreased -95.61

What is Spero Therapeutics Inc (SPRO)'s earnings per share (EPS) for the last quarter?

Spero Therapeutics Inc. EPS for the last quarter amounts to -0.13 USD, decreased -48.00

How many employees does Spero Therapeutics Inc (SPRO). have?

Spero Therapeutics Inc (SPRO) has 25 emplpoyees as of July 05 2026.

What is Spero Therapeutics Inc (SPRO) market cap?

Today SPRO has the market capitalization of 127.38M USD.